Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L GELLER

Showing results (471-480 of 489) with videos related to

Pageof 49
Sort By:
JACC. Heart Failure|June 16, 2014
Charting a roadmap for heart failure biomarker studiesTariq Ahmad, Mona Fiuzat, Michael J Pencina, et al.
American Heart Journal|September 11, 2013
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trialStephen E Kimmel, Benjamin French, Jeffrey L Anderson, et al.
The Lancet. Oncology|October 4, 2011
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trialAmrita Krishnan, Marcelo C Pasquini, Brent Logan, et al.
The Journal of Clinical Endocrinology and Metabolism|August 28, 2013
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extensionHenry G Bone, Roland Chapurlat, Maria-Luisa Brandi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic SyndromesBart L Scott, Marcelo C Pasquini, Brent R Logan, et al.
Transplantation and Cellular Therapy|March 29, 2021
Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical TrialBart L Scott, Marcelo C Pasquini, Mingwei Fei, et al.
JTCVS Structural and Endovascular|May 14, 2026
Association of tricuspid regurgitation with clinical events and quality of life after surgery for severe ischemic mitral regurgitationRaymond J Strobel, Benjamin P Kramer, Jessica R Overbey, et al.
Journal of the American College of Cardiology|July 26, 2014
Management practices and major infections after cardiac surgeryAnnetine C Gelijns, Alan J Moskowitz, Michael A Acker, et al.
The New England Journal of Medicine|November 20, 2013
Mitral-valve repair versus replacement for severe ischemic mitral regurgitationMichael A Acker, Michael K Parides, Louis P Perrault, et al.
The New England Journal of Medicine|November 10, 2015
Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral RegurgitationDaniel Goldstein, Alan J Moskowitz, Annetine C Gelijns, et al.
Pageof 49

Showing results (471-480 of 489) with videos related to

Sort By:
Pageof 49
JACC. Heart Failure|June 16, 2014
Charting a roadmap for heart failure biomarker studiesTariq Ahmad, Mona Fiuzat, Michael J Pencina, et al.
American Heart Journal|September 11, 2013
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trialStephen E Kimmel, Benjamin French, Jeffrey L Anderson, et al.
The Lancet. Oncology|October 4, 2011
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trialAmrita Krishnan, Marcelo C Pasquini, Brent Logan, et al.
The Journal of Clinical Endocrinology and Metabolism|August 28, 2013
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extensionHenry G Bone, Roland Chapurlat, Maria-Luisa Brandi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2017
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic SyndromesBart L Scott, Marcelo C Pasquini, Brent R Logan, et al.
Transplantation and Cellular Therapy|March 29, 2021
Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical TrialBart L Scott, Marcelo C Pasquini, Mingwei Fei, et al.
JTCVS Structural and Endovascular|May 14, 2026
Association of tricuspid regurgitation with clinical events and quality of life after surgery for severe ischemic mitral regurgitationRaymond J Strobel, Benjamin P Kramer, Jessica R Overbey, et al.
Journal of the American College of Cardiology|July 26, 2014
Management practices and major infections after cardiac surgeryAnnetine C Gelijns, Alan J Moskowitz, Michael A Acker, et al.
The New England Journal of Medicine|November 20, 2013
Mitral-valve repair versus replacement for severe ischemic mitral regurgitationMichael A Acker, Michael K Parides, Louis P Perrault, et al.
The New England Journal of Medicine|November 10, 2015
Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral RegurgitationDaniel Goldstein, Alan J Moskowitz, Annetine C Gelijns, et al.
Pageof 49